Methyl 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate [2] 7.50 g Methyl 4-bromo-3-methylbenzoate (32.7 mmol, 1.00 eq) was dissolved in degassed DMSO (50 mL). 9.65 g KOAc (98.2 mmol, 3.00 eq), 9.15 g [B(pin) 2 ] 2 (36.0 mmol, 1.10 eq) and 535 mg [PdCl 2 (dppf)]•DCM (655 µmol, 2 mol%) were added. The reaction mixture was stirred at 80°C for 18 h. The solvent was removed under reduced pressure and the residue was diluted was H 2 O (500 mL). The mixture was extracted with DCM (3 x 300 mL). The solvent of the combined organic layers was removed under reduced pressure and the crude product was purified with column chromatography over silica gel (DCM). Methyl 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)benzoate (9.02 g, 99%) was obtained as brown, viscous oil.
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Methyl 3-(bromomethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate [3] 3.00 g Methyl 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl)benzoate (10.9 mmol, 1.00 eq) was dissolved in MeCN (70 mL). 388 mg NBS (2.18 mmol, 0.20 eq) and 17.8 mg AIBN (109 µmol, 1mol%) was added. The reaction mixture was heated to 70 °C and 1.55 g NBS (8.72 mmol, 0.80 eq) in MeCN (15 mL) was added over 1 h. After completed addition, the reaction mixture was stirred 6 h at 70°C. The solvent was removed under reduced pressure and the crude product purified with column chromatography over silica gel (DCM) . [3] 3 [4] 2.00 g 3,4-dihydroxybenzoic acid (13.0 mmol, 1.00 eq) was suspended in CH 2 Cl 2 (70 mL). 11.0 mL DIPEA (64.9 mmol, 5.00 eq) and 4.91 mL Ac 2 O (51.9 mmol, 4.00 eq) were added. After stirring for 1 h at RT, the solvent was removed under reduced pressure. The crude product was purified with column chromatography over silica gel (DCM/MeOH 100:1 + 1% AcOH) and 3,4diacetoxybenzoic acid (2.55 g, 83%) was obtained as colorless solid. 
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1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-5-carboxylic acid
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CMP and cap synthesis CMP manual peptide synthesis (Protocol A):
The manual peptide synthesis was performed using the following protocol.
1)
Stirring in Toluene/DMSO (3:1) for 20 min.
2) 3 x washing with Toluene/DMSO (3:1), CH 2 Cl 2 and Toluene/DMSO (3:1).
3) 2 x cleavage of the Fmoc protection group with 30% piperidine in DMSO +1% Triton X-100 for 10 min at 70 °C. Steps 2-5e were performed as long as the peptide was fully assembled. 
Resin cleavage and final deprotection:
5)
Coupling with Fmoc-Xaa-OH (3.0 eq), HOBt (3.0 eq), HBTU (3.0 eq) and DIPEA (6.0 eq) in Toluene/DMSO (3:1) for 30 min at 70 °C after 10 min preactivation at RT.
Steps 2-5 were performed as long as the peptide was fully assembled. +) 
HRMS (ESI(
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Cat-D-Lys(Cat)-D-Lys(Cat)-NH2 (6)
Cat-Lys(Cat)-Lys(Cat)-NH 2 
